Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma after the US regulator gave it a priority review. The French pharma group ...
We have audited the standalone financial statements of AGS Transact Technologies Limited (the "Company")(in which are included financial information from an Employee Stock Option Plan (ESOP) Trust) ...
During the year under review, the revenue from operations on a standalone basis was 10,433.82 Million as compared to 12,102.43 Million in the previous year. The revenue from operations on a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback